
|Articles|February 26, 2007
Helixate FS, Mix2Vial now packaged together
Advertisement
CSL Behring has begun packaging Helixate FS, its advanced recombinant FVIII (rFVIII) factor product for the treatment of hemophilia A, with Mix2Vial, its needle-free transfer device. The new packaging was developed in response to comprehensive market research of customers and to meet the latest OSHA requirements. For more information, visit
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves XFG-Targeted COVID-19 Vaccines From Multiple Companies
2
FDA Approves Stelara for Pediatric Ulcerative Colitis
3
COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients
4
Study Finds Dormant Viruses Reactivate During COVID-19
5




























